BR0008917A - Compostos - Google Patents

Compostos

Info

Publication number
BR0008917A
BR0008917A BR0008917-6A BR0008917A BR0008917A BR 0008917 A BR0008917 A BR 0008917A BR 0008917 A BR0008917 A BR 0008917A BR 0008917 A BR0008917 A BR 0008917A
Authority
BR
Brazil
Prior art keywords
compounds
polynucleotides
casb618
polypeptides
methods
Prior art date
Application number
BR0008917-6A
Other languages
English (en)
Inventor
Claudine Elvire Marie Bruck
Jean-Pol Cassart
Thierry Coche
Carlota Vinals Y De Bassols
Original Assignee
Smithkline Beecham Biolog
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9905607.9A external-priority patent/GB9905607D0/en
Priority claimed from GBGB9920590.8A external-priority patent/GB9920590D0/en
Application filed by Smithkline Beecham Biolog filed Critical Smithkline Beecham Biolog
Publication of BR0008917A publication Critical patent/BR0008917A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Use Of Switch Circuits For Exchanges And Methods Of Control Of Multiplex Exchanges (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Patente de Invenção: "COMPOSTOS". O polipeptídeo CASB618 e polinucleotídeos e métodos para a produção de tais polipeptídeos através de técnicas recombinantes são descritos. São também descritos métodos para a utilização dos polipeptídeos CASB618 e polinucleotídeos em diagnósticos e vacinas para tratamento profilático e terapêutico de cânceres, particularmente cânceres de ovário e cólon, doenças auto-imunes e condições relacionadas.
BR0008917-6A 1999-03-11 2000-03-09 Compostos BR0008917A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9905607.9A GB9905607D0 (en) 1999-03-11 1999-03-11 Novel compounds
GBGB9920590.8A GB9920590D0 (en) 1999-09-01 1999-09-01 Novel compounds
PCT/EP2000/002048 WO2000053748A2 (en) 1999-03-11 2000-03-09 Casb618 polynucleotides and polypeptides and their use

Publications (1)

Publication Number Publication Date
BR0008917A true BR0008917A (pt) 2002-01-15

Family

ID=26315257

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0008917-6A BR0008917A (pt) 1999-03-11 2000-03-09 Compostos

Country Status (22)

Country Link
US (2) US7470782B2 (pt)
EP (1) EP1165778B1 (pt)
JP (1) JP2002538787A (pt)
KR (1) KR100674784B1 (pt)
CN (1) CN100430478C (pt)
AT (1) ATE342727T1 (pt)
AU (1) AU756398B2 (pt)
BR (1) BR0008917A (pt)
CA (1) CA2366147A1 (pt)
CZ (1) CZ20013268A3 (pt)
DE (1) DE60031383T2 (pt)
DK (1) DK1165778T3 (pt)
ES (1) ES2273670T3 (pt)
HK (1) HK1044794B (pt)
HU (1) HUP0200366A2 (pt)
IL (2) IL145047A0 (pt)
NO (1) NO20014293L (pt)
NZ (1) NZ513838A (pt)
PL (1) PL350991A1 (pt)
PT (1) PT1165778E (pt)
TR (1) TR200102781T2 (pt)
WO (1) WO2000053748A2 (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ303468B6 (cs) 2000-02-23 2012-10-03 Smithkline Beecham Biologicals S. A. Imunogenní smes a farmaceutická smes
US7811574B2 (en) 2000-02-23 2010-10-12 Glaxosmithkline Biologicals S.A. Tumour-specific animal proteins
WO2007106509A2 (en) * 2006-03-14 2007-09-20 Genizon Biosciences, Inc. Methods and means for nucleic acid sequencing
ES2539042T3 (es) 2006-06-02 2015-06-25 Glaxosmithkline Biologicals S.A. Procedimiento de identificación de si un paciente será respondedor o no a inmunoterapia
PT2148697E (pt) 2007-05-24 2012-12-24 Glaxosmithkline Biolog Sa Composição liofilizada de wt-1 contendo cpg
KR20120014054A (ko) 2009-05-27 2012-02-15 글락소스미스클라인 바이오로지칼즈 에스.에이. Ｃａｓｂ7439 작제물
GB0917457D0 (en) 2009-10-06 2009-11-18 Glaxosmithkline Biolog Sa Method

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5688657A (en) * 1988-03-31 1997-11-18 International Bio-Immune Systems, Inc. Monoclonal antibodies against human colon carcinoma-associated antigens and uses therefor
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
US5840839A (en) 1996-02-09 1998-11-24 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Alternative open reading frame DNA of a normal gene and a novel human cancer antigen encoded therein
US5840871A (en) * 1997-01-29 1998-11-24 Incyte Pharmaceuticals, Inc. Prostate-associated kallikrein
GB9806095D0 (en) * 1998-03-20 1998-05-20 Smithkline Beecham Biolog Novel compounds
GB9806164D0 (en) * 1998-03-20 1998-05-20 Smithkline Beecham Biolog Novel compounds
WO2000061596A1 (en) * 1999-04-09 2000-10-19 Human Genome Sciences, Inc. 50 human secreted proteins
US7105315B2 (en) 1999-06-16 2006-09-12 Incyte Genomics, Inc. Transmembrane protein differentially expressed in cancer
WO2000056891A2 (en) * 1999-03-22 2000-09-28 Incyte Pharmaceuticals, Inc. Human transmembrane proteins

Also Published As

Publication number Publication date
HK1044794B (zh) 2007-05-18
US20090202577A1 (en) 2009-08-13
KR20020008125A (ko) 2002-01-29
US20060052593A1 (en) 2006-03-09
PT1165778E (pt) 2007-01-31
ES2273670T3 (es) 2007-05-16
JP2002538787A (ja) 2002-11-19
WO2000053748A3 (en) 2001-01-11
ATE342727T1 (de) 2006-11-15
TR200102781T2 (tr) 2002-01-21
HK1044794A1 (en) 2002-11-01
DE60031383D1 (de) 2006-11-30
HUP0200366A2 (en) 2002-06-29
AU756398B2 (en) 2003-01-09
PL350991A1 (en) 2003-02-24
CA2366147A1 (en) 2000-09-14
NZ513838A (en) 2003-02-28
EP1165778B1 (en) 2006-10-18
CN1370231A (zh) 2002-09-18
EP1165778A2 (en) 2002-01-02
IL145047A (en) 2008-11-03
AU3287700A (en) 2000-09-28
CN100430478C (zh) 2008-11-05
DE60031383T2 (de) 2007-11-15
US7470782B2 (en) 2008-12-30
KR100674784B1 (ko) 2007-01-25
NO20014293D0 (no) 2001-09-04
CZ20013268A3 (cs) 2002-02-13
NO20014293L (no) 2001-11-12
IL145047A0 (en) 2002-06-30
WO2000053748A2 (en) 2000-09-14
DK1165778T3 (da) 2007-02-12

Similar Documents

Publication Publication Date Title
TR200003347T2 (tr) Neisseria meningitidis'denBASB029 polinükleotidleri ve polipeptidler
BR0008917A (pt) Compostos
UA72875C2 (uk) БІЛКИ, ЯКІ ЗВ'ЯЗУЮТЬСЯ З <font face="Symbol">b</font>-АМІЛОЇДНИМ ПЕПТИДОМ ТА ПОЛІНУКЛЕОТИДИ, ЩО ЇХ КОДУЮТЬ
BR9911601A (pt) Polipeptìdios antigênicos de neisseria meningitidis, polinucleotìdeos correspondentes e anticorpos protetores
BR0009358A (pt) Compostos
ATE281524T1 (de) Moraxella catarrhalis pilq proteine
GB9809683D0 (en) Novel compounds
BR9914492A (pt) Polipeptìdos basb034 de moraxella catarrhalis e usos dos mesmos
DE69928931D1 (de) Moraxella catarrhalis polynukleotide und polypeptide
PL345193A1 (en) Basb027 proteins and genes from moraxella catarrhalis
BR9911773A (pt) Compostos de moraxella catarrhalis
ATE454452T1 (de) Basb118 polypeptid und polynukleotid aus moraxella catarrhalis
ATE515511T1 (de) Nicht-typisierbare haemophilus influenzae basb201 polypeptide und polynukleotide und deren verwendungen
HK1047954A1 (zh) 衍生自黏膜炎莫拉氏菌的免疫源性多肽及其用途
ATE360073T1 (de) Basb119 polypeptid und polynukleotid aus moraxella catarrhalis
DE60019614D1 (de) Moraxella catarrhalis antigen basb117
ATE311458T1 (de) Basb111 polypeptid und polynukleotid aus moraxella catharralis
WO2000043509A3 (en) Polynucleotides and their applications in diagnostics
DE60019613D1 (de) Moraxella catarrhalis antigen basb120
ATE368686T1 (de) Polypeptide aus moraxella (branhamella) catarrhalis

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) 8O, 10 (VIII E IX), 13, 18 (III) E 25 DA LPI.

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.